Rivaroxaban for thromboprophylaxis [4]

New England Journal of Medicine

Volumn 359, Issue 20, 2008, Pages 2174-

  Lippi, Giuseppe ^a   Franchini, Massimo ^b   Targher, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Servizio di Immunoematologia e Trasfusione   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; RIVAROXABAN;

BLEEDING; CHRONIC PAIN; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; LUNG EMBOLISM; MEDICAL SPECIALIST; ORTHOPEDICS; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RANGE OF MOTION; RISK ASSESSMENT; TOTAL KNEE REPLACEMENT; TREATMENT OUTCOME; WOUND HEALING;

EID: 56249108762     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc081524     Document Type: Letter

References (2)

1. Franchini M, Lippi G. Antagonists of activated factor X and thrombin: innovative antithrombotic agents. Curr Vasc Pharmacol 2007;5:121-8.
2. Weitz JI, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:Suppl:234S-256S. [Erratum, Chest 2008;134:473.]